Bioassay Works

Executive Summary

BioAssay Works (BAW) is a US-based CDMO specializing in lateral flow immunoassays (LFAs) and gold nanoparticle reagents. Founded in 2008 and headquartered in Frederick, Maryland, the company offers custom assay development, contract manufacturing, and gold conjugation services for diagnostic and industrial applications. BAW's core technology aims to achieve ELISA-level sensitivity in rapid, point-of-care test formats, positioning it as a key partner for companies seeking to develop high-performance rapid diagnostics. With its focus on gold nanoparticle conjugation—a critical component in many LFAs—BAW provides specialized expertise that differentiates it from larger, more generalized CDMOs. BAW operates in a growing market driven by demand for decentralized testing and rapid diagnostics in infectious disease, cardiac markers, and environmental monitoring. Its ability to deliver sensitive, cost-effective LFAs could attract partnerships with diagnostic firms aiming to bring new POC tests to market. However, as a relatively small private company, BAW faces competition from larger CDMOs with broader capabilities. Near-term growth will likely depend on securing repeat contracts and expanding manufacturing capacity. Overall, BAW is well-positioned to capitalize on the shift toward point-of-care testing, provided it can scale operations and maintain technological edge.

Upcoming Catalysts (preview)

• 2026Manufacturing capacity expansion or new facility announcement60% success
• 2026Strategic partnership with a major diagnostic company50% success
• 2026Publication of validation data demonstrating ELISA-level sensitivity in a commercial LFA40% success